AffyImmune Therapeutics to Present at 2023 Cell & Gene Meeting on the Mesa

October 3, 2023

NATICK, Mass., October 3, 2023 – AffyImmune Therapeutics, Inc., announced today that Matt Britz, Chief Operating Officer will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California and livestreamed globally.

“We are looking forward to connecting with fellow leaders of cell and gene therapy; this is a great opportunity to help educate the industry on AffyImmune and our Tune & Track system,” said Mr. Britz. “Earlier this year at ASCO, we presented positive safety and early efficacy results from our Phase 1 study of AIC100 in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers, and we’re excited to continue education about our platform.”

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

The following are specific details regarding AffyImmune’s presentation at the conference:

Event: 2023 Cell & Gene Meeting on the Mesa
Date: Tuesday, October 10th
Time: 5:00 p.m. PT
Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011

Virtual attendance is available which includes a livestream of AffyImmune’s presentation and the ability to view all conference sessions on-demand. Please visit for full information including registration.

Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Savannah Bryant at and interested media should contact Stephen Majors at

Contact Information:

Argot Partners

Media: Stephanie Jacobson

IR: Jonathan Nugent


AffyImmune Therapeutics, Inc.

Matt Britz, Chief Operating Officer